Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Date:2/26/2009

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression

NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from an ongoing Phase 1/2 study of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. The data, which was presented earlier today in a poster featured at the 12th International Multiple Myeloma Workshop in Washington, DC, highlights a subset analysis of the bortezomib-relapsed patients who were evaluable at the time of this report.

Data from this Phase 1/2 study were previously presented in December 2008 at the American Society of Hematology meeting via an oral presentation entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (VELCADE(R)) in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Treated with Bortezomib." Updated results from this fully enrolled study are as follows:

Trial Summary:

Eighty-four patients were enrolled in a combined Phase 1/2 study (18 patients in the Phase I component and 66 patients in the Phase II component). At the time of this analysis, 73 patients were evaluable for response. Median prior lines of therapy was 5 (range 1 - 13), including; 100% of patients had been treated with bortezomib (50% of the patients were previously treated with at least 2 bortezomib-based therapies and 81% were previously treated with bortezomib plus dexamethasone); 98% of patients were previously treated with dexamethasone; 99% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had prior stem c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... II proof of concept clinical study investigating the ... in the treatment of chronic pruritus in patients ... clinically meaningful improvement from baseline by tradipitant (40.5mm ... 100mm unit Visual Analog Scale (VAS) for itch, ...
(Date:3/4/2015)...  The strongest driver of demand in the ... population, according to Kalorama Information. The finding was ... market research publisher, Global Orthopedic Device Market ... such as obesity is contributing to the rise ... designs and the trend toward cost effective solutions ...
(Date:3/4/2015)... 4, 2015 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China, today announced its ... 2014. Fourth Quarter 2014 Financial Highlights ... of 2014 increased by 36.2%, or 36.8% excluding the ... million from $42.6 million in the same quarter of ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22
... the leading public medical equipment marketplace, and the leader ... has launched its Certified Parts Vendor (CPV) Program. ... parts vendors, provide enhanced vendor due diligence and create ... CPV Program is create stronger direct buyer-seller relationships. , ...
... 8 Endologix, Inc. (Nasdaq: ELGX ), developer of ... has become aware that Cook Medical has filed a lawsuit ... Endologix infringes two of Cook,s U.S. patents. , John McDermott, ... become aware of the lawsuit filed by Cook alleging that ...
Cached Medicine Technology:DOTmed Announces Certified Parts Vendor (CPV) Program 2Endologix Comments on Alleged Patent Infringement 2
(Date:3/4/2015)... 04, 2015 Organic Valley, the nation’s largest ... announced its cause campaign to Save the Bros, http://savethebros.com/ ... making a difference to Bros everywhere. To date, the ... Facebook. The video was named Adweek’s best commercial of ... Mashable and Digiday, among other media outlets. , “We ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 RapidScale, ... 2015, in Las Vegas, Nevada, on March 16th-18th. They ... RapidScale will have some of its top engineering executives ... advances in the RapidScale solution set. Attendees include William ... Senior Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Information ... John Dvorak has joined the company as ... charting the technology focus for the company, including customer-centric ... Dvorak brings 20 years of experience as a technology ... in diverse roles at the FBI including oversight of ...
(Date:3/4/2015)... Plungerhead has partnered with the Boot ... after their service to the country. The new partnership, ... social media and several national special events, as well ... special retail promotion of Plungerhead Lodi Zinfandel and Plungerhead ... , “There is a vital need and responsibility ...
(Date:3/4/2015)... 2015 The Alliance for Regenerative ... its upcoming fifth annual Advanced Therapies Summit next ... event this year will feature five expert-led interactive ... the field’s leading companies and organizations. , ... and clinical researchers from the advanced therapies community ...
Breaking Medicine News(10 mins):Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 2Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 3Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3
... ... Device, MOUNTAIN VIEW, Calif., ... software and IP for semiconductor design,and manufacturing, today announced that Oticon has ... using Synopsys, IC Compiler design planning and place-and-route,product, which is part of ...
... autoantibody-secreting cells, have emerged as promising new therapeutic ... In particular, B cell depletion with the ... patients resistant to standard disease-modifying antirheumatic drugs (DMARDs) ... In large trials, about half of these hard-to-treat ...
... As pro-lifers across the,nation prepare to protest the ... for Women (NOW) seeks supporters for,counter-protests., "The pill ... League,decided this campaign would be the best way to ... for American Life League and,project manager of Protest the ...
... affect number of infections, need for hospitalization, study ... milk,s protection against respiratory infections is stronger in girls ... the long-held belief that immune system chemicals passed from ... from disease. , The Johns Hopkins Children,s Center-led ...
... Southwestern Medical Center physician and other researchers have developed ... a patient being cancer free 12 years after initial ... nomogram, uses tumor and patient characteristics to maximize predictive ... cancer,s return can help clinicians counsel patients and to ...
... Featuring Live Performances by The Who and Tribute,Bands Pearl Jam, Foo ... July 17 at 9:00pm* from the Pauley Pavilion ... first time ever, fans will,have the opportunity to see some of ... on sale for the network,s third annual "VH1 Rock,Honors" event paying ...
Cached Medicine News:Health News:Oticon Tapes Out Innovative Hearing-Aid DSP Using Synopsys IC Compiler 2Health News:Oticon Tapes Out Innovative Hearing-Aid DSP Using Synopsys IC Compiler 3Health News:Study of anti-CD20 therapy effective B cell depletion 2Health News:ALL vs. NOW: Pill Protest Heating Up 2Health News:ALL vs. NOW: Pill Protest Heating Up 3Health News:Breast-Feeding More Protective for Girls Than Boys 2Health News:New model predicts whether patients will be free of renal cancer 12 years after initial treatment 2Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 2Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 3Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 4Health News:'VH1 Rock Honors: The Who' Tickets Go on Sale Sunday, June 8 with Proceeds to Benefit the Efforts of Multiple Charities 5
... treat heart rhythms that are abnormally fast ... often are used to treat sudden cardiac ... reduce the SCD mortality rate for these ... to less than 2 percent as verified ...
... Frequency Ultrasound system is the most advanced ... available. The HF35-50 allows users to perform ... segment with 35MHz or 50MHz probes or ... 20 MHz sealed B-probe. , ,The Macintosh ...
Sonogage introduces a new generation of A-Scan biometers for visual axis measurements and IOL calculations. The Eye-Scan™ employs the latest electronic and transducer technologies for unsurpass...
... display and IOL power calculation software. All ... module with SRK II, SRKT, Holladay Dioptimum ... 5000e and DGH 5100e are equipped with ... of short readings. The only A-Scan in ...
Medicine Products: